CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 37 enrolled
Drug / intervention
HMB (beta-hydroxy beta-methylbutyrate)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03628365
NCT03628365N/ACompleted
CompareCT.gov

Can Beta-Hydroxy-beta-Methylbutyrate (HMB) Supplementation Counteract Muscle Catabolism in Critically Ill Patients? A Randomized Controlled Trial

Mette M Berger·interventional·Posted Aug 14, 2018·Updated Aug 21, 2020

In Brief

A clinical study evaluating HMB (beta-hydroxy beta-methylbutyrate) for Critical Illness and Muscle Weakness. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The rapid decline of muscle mass and function in mechanically ventilated critically ill patients is associated with prolonged length of mechanical ventilation, prolonged intensive care (ICU) and hospital stay, increased ICU and hospital mortality, and prolonged impairment in physical function and quality of life. High protein feeding only partially attenuates the muscle loss. The aim is to study the impact of HMB (3 g/day) on the muscle mass of the critically ill patients from day 4 of their admission to maximum 30 days, but at least for 10 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCritical Illness, Muscle Weakness
CountriesSwitzerland
CollaboratorsTexas A&M University

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 14, 2018
Enrollment StartSep 17, 2018
Primary CompletionJan 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.9 years ago

Interventions

HMB (beta-hydroxy beta-methylbutyrate)dietary

1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)